Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05180097 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Dec 31, 2025 to Dec 31, 2026
    • Study completion date: Jun 30, 2026 to Dec 31, 2026
    v28
  2. Primary completion date: Jun 30, 2025 to Dec 31, 2025
    • Study sites: 17 to 18
    v27
  3. Study sites: 16 to 17v26
  4. Study sites: 13 to 16v25
  5. Study sites revised (13)v24
Show 22 earlier versionsHide 22 earlier versions
  1. Collaborators revised (3)v23
  2. Study sites revised (13)v22
  3. Collaborators: 2 to 3v21
  4. Study sites: 12 to 13v20
  5. Study sites revised (12)v19
  6. Primary completion date: Jun 30, 2024 to Jun 30, 2025
    • Study completion date: Jun 30, 2025 to Jun 30, 2026
    v18
  7. Study sites: 11 to 12v17
  8. Study sites: 10 to 11v16
  9. Re-verified, no change to tracked fieldsv15
  10. Eligibility criteria expanded, about 18 words
    • Secondary endpoints revised (12)
    • Study description revised
    v14
  11. Start date: Mar 3, 2022 to Nov 1, 2022v13
  12. Study sites: 9 to 10v12
  13. Study sites: 7 to 9v11
  14. Site details revised at 1 of 7 sitesv10
  15. Study sites: 5 to 7v9
  16. Study sites: 3 to 5v8
  17. Study sites: 2 to 3v7
  18. Study sites: 1 to 2v6
  19. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Aug 31, 2022 to Mar 3, 2022
    v5
  20. Start date: Mar 30, 2022 to Aug 31, 2022v4
  21. Start date: Apr 30, 2022 to Mar 30, 2022v3
  22. Start date: Dec 31, 2021 to Apr 30, 2022v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is being done to determine if two new drugs can shrink or eliminate classical Hodgkins lymphoma.
Trial Details
NCT Number NCT05180097
Lead Sponsor Canadian Cancer Trials Group
Collaborators: Merck Sharp & Dohme LLC, Pfizer, Australasian Leukaemia and Lymphoma Group
Conditions
(from sponsor)		 Hodgkin Lymphoma
Related terms Hodgkin Disease
Enrollment 84 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov